Patents by Inventor Jean-Jacques Simon
Jean-Jacques Simon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11529361Abstract: The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.Type: GrantFiled: November 6, 2020Date of Patent: December 20, 2022Assignee: UNION therapeutics A/SInventors: Morten Otto Alexander Sommer, Rasmus Vendler Toft-Kehler, Daniel Jean Jacques Simon
-
Patent number: 11331327Abstract: The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Grain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.Type: GrantFiled: June 12, 2020Date of Patent: May 17, 2022Assignee: UNION therapeutics A/SInventors: Emilie Flora Aurore Delavenne, Daniel Jean Jacques Simon, Morten Otto Alexander Sommer, Rasmus Vendler Toft-Kehler
-
Patent number: 11324761Abstract: The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Grain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.Type: GrantFiled: June 12, 2020Date of Patent: May 10, 2022Assignee: UNION therapeutics A/SInventors: Emilie Flora Aurore Delavenne, Daniel Jean Jacques Simon, Morten Otto Alexander Sommer, Rasmus Vendler Toft-Kehler
-
Patent number: 11285164Abstract: The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenesGrain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.Type: GrantFiled: June 12, 2020Date of Patent: March 29, 2022Assignee: UNION therapeutics A/SInventors: Emilie Flora Aurore Delavenne, Daniel Jean Jacques Simon, Morten Otto Alexander Sommer, Rasmus Vendler Toft-Kehler
-
Patent number: 11283304Abstract: A rectenna device (400) for converting incident light to electrical energy is disclosed. The rectenna device comprises a substrate (402), a first metallic layer (404) having a predefined thickness deposited on top of the substrate, a rectifying element (405) deposited on top of the first metallic layer, a second metallic layer (408) deposited on top of said rectifying element and configured to collect electromagnetic waves of the incident light and to couple it into plasmonic waves within the rectenna device, the second metallic layer comprising an array of a plurality of metallic patches (410) spaced from each other according to a predefined spacing, each metallic patch having predefined dimensions.Type: GrantFiled: November 28, 2018Date of Patent: March 22, 2022Assignees: UNIVERSITE D'AIX-MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE CENTRALE DE MARSEILLE, UNIVERSITE DE TOULONInventors: David Duche, Ludovic Escoubas, Ujwol Palanchoke, Jean-Jacques Simon, Teodor Silvius Balaban
-
Patent number: 11277095Abstract: A method for producing a multicoloured optoelectronic device is provided as well as a device produced with that method. An electrically conducting substrate including a first and second portion adjacent to the first portion is obtained. Then a first photoactive material having optical properties in a first frequency range is deposited on the first portion and a second photoactive material differing from the first photoactive material having optical properties in a second frequency range is deposited on the second portion, the first photoactive material contacting the second photoactive material, forming a photoactive layer of the multicoloured optoelectronic device.Type: GrantFiled: February 23, 2018Date of Patent: March 15, 2022Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ D'AIX-MARSEILLEInventors: Jörg Ackermann, Sadok Ben Dkhil, Olivier Margeat, David Duché, Ludovic Escoubas, Jean-Jacques Simon, Christine Videlot-Ackermann
-
Publication number: 20210308153Abstract: The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.Type: ApplicationFiled: November 6, 2020Publication date: October 7, 2021Inventors: Morten Otto Alexander Sommer, Ramus Vendler Toft-Kehler, Daniel Jean Jacques Simon
-
Patent number: 10857164Abstract: The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.Type: GrantFiled: October 1, 2019Date of Patent: December 8, 2020Assignee: UNION therapeutics A/SInventors: Morten Otto Alexander Sommer, Ramus Vendler Toft-Kehler, Daniel Jean Jacques Simon
-
Publication number: 20200358321Abstract: A rectenna device (400) for converting incident light to electrical energy is disclosed. The rectenna device comprises a substrate (402), a first metallic layer (404) having a predefined thickness deposited on top of the substrate, a rectifying element (405) deposited on top of the first metallic layer, a second metallic layer (408) deposited on top of said rectifying element and configured to collect electromagnetic waves of the incident light and to couple it into plasmonic waves within the rectenna device, the second metallic layer comprising an array of a plurality of metallic patches (410) spaced from each other according to a predefined spacing, each metallic patch having predefined dimensions.Type: ApplicationFiled: November 28, 2018Publication date: November 12, 2020Inventors: David DUCHE, Ludovic ESCOUBAS, Ujwol PALANCHOKE, Jean-Jacques SIMON, Teodor Silvius BALABAN
-
Publication number: 20200306271Abstract: The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Grain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.Type: ApplicationFiled: June 12, 2020Publication date: October 1, 2020Inventors: Emilie Flora Aurore DELAVENNE, Daniel Jean Jacques SIMON, Morten Otto Alexander SOMMER, Rasmus Vendler TOFT-KEHLER
-
Publication number: 20200306269Abstract: The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosam-ide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenesGrain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appear-ance of resistant mutants compared to commonly used topical antibiotics.Type: ApplicationFiled: June 12, 2020Publication date: October 1, 2020Inventors: Emilie Flora Aurore DELAVENNE, Daniel Jean Jacques SIMON, Morten Otto Alexander SOMMER, Rasmus Vendler TOFT-KEHLER
-
Publication number: 20200306270Abstract: The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Grain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.Type: ApplicationFiled: June 12, 2020Publication date: October 1, 2020Inventors: Emilie Flora Aurore DELAVENNE, Daniel Jean Jacques SIMON, Morten Otto Alexander SOMMER, Rasmus Vendler TOFT-KEHLER
-
Patent number: 10758553Abstract: The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Grain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.Type: GrantFiled: September 7, 2018Date of Patent: September 1, 2020Assignee: UNION therapeutics A/SInventors: Emilie Flora Aurore Delavenne, Daniel Jean Jacques Simon, Morten Otto Alexander Sommer, Rasmus Vendler Toft-Kehler
-
Publication number: 20200093839Abstract: The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.Type: ApplicationFiled: October 1, 2019Publication date: March 26, 2020Inventors: Morten Otto Alexander Sommer, Ramus Vendler Toft-Kehler, Daniel Jean Jacques Simon
-
Publication number: 20190393836Abstract: A method for producing a multicoloured optoelectronic device is provided as well as a device produced with that method. An electrically conducting substrate including a first and second portion adjacent to the first portion is obtained. Then a first photoactive material having optical properties in a first frequency range is deposited on the first portion and a second photoactive material differing from the first photoactive material having optical properties in a second frequency range is deposited on the second portion, the first photoactive material contacting the second photoactive material, forming a photoactive layer of the multicoloured optoelectronic device.Type: ApplicationFiled: February 23, 2018Publication date: December 26, 2019Inventors: Jörg ACKERMANN, Sadok BEN DKHIL, Olivier MARGEAT, David DUCHÉ, Ludovic ESCOUBAS, Jean-Jacques SIMON, Christine VIDELOT-ACKERMANN
-
Patent number: 10463680Abstract: The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhea and C. difficile associated colitis.Type: GrantFiled: May 27, 2016Date of Patent: November 5, 2019Assignee: UNION therapeutics A/SInventors: Morten Otto Alexander Sommer, Rasmus Vendler Toft-Kehler, Daniel Jean Jacques Simon
-
Publication number: 20190099433Abstract: The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Grain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.Type: ApplicationFiled: September 7, 2018Publication date: April 4, 2019Inventors: Emilie Flora Aurore DELAVENNE, Daniel Jean Jacques SIMON, Morten Otto Alexander SOMMER, Rasmus Vendler TOFT-KEHLER
-
Publication number: 20180207179Abstract: The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.Type: ApplicationFiled: May 27, 2016Publication date: July 26, 2018Applicant: ANTIBIOTX A/SInventors: Morten Otto Alexander SOMMER, Rasmus Vendler TOFT-KEHLER, Daniel Jean Jacques SIMON
-
Patent number: 9949988Abstract: The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Gram positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.Type: GrantFiled: July 28, 2017Date of Patent: April 24, 2018Assignee: AntibioTx A/SInventors: Emilie Flora Aurore Delavenne, Daniel Jean Jacques Simon, Morten Otto Alexander Sommer, Rasmus Vendler Toft-Kehler
-
Patent number: 9948174Abstract: The protection device for providing protection against short-circuits upstream from an electrical power supply module having an inlet filter with at least one capacitor and an inductor and having a converter with components associated with a plurality of freewheel diodes includes at least one auxiliary winding and a dissipator element associated with the inlet filter, thereby making it possible to provide an inlet filter of small size without over dimensioning the freewheel diodes.Type: GrantFiled: October 15, 2014Date of Patent: April 17, 2018Assignee: Safran Electrical & PowerInventors: Jean-Jacques Simon, Nicolas Dheilly, Roland Casimir